Telomir Pharmaceuticals Secures $3M Investment to Advance Age-Reversal Research
TL;DR
Telomir Pharmaceuticals secures $3 million equity investment from The Bayshore Trust, offering a competitive advantage for strategic expansion.
Telomir-1 and Telomir-Ag2 are cutting-edge drug candidates targeting age-reversal and drug-resistant infections respectively, with an IND submission planned by year-end.
Telomir's innovative drug development aims to enhance longevity and quality of life for both humans and animals, contributing positively to healthcare advancements.
Telomir Pharmaceuticals' commitment to shareholder-friendly financing with no warrants or toxic structures sets a new standard for ethical pharmaceutical investments.
Found this article helpful?
Share it with your network and spread the knowledge!
Telomir Pharmaceuticals (NASDAQ: TELO) has secured a $3 million equity investment from its largest shareholder, The Bayshore Trust, signaling continued confidence in the company's innovative approach to age-related medical research. The investment involves the purchase of 1 million restricted shares at $3.00 per share, representing an 18% premium to the stock's previous closing price.
The funding will support the company's advanced pipeline, which includes two key drug candidates: Telomir-1, a first-in-class age-reversal molecule, and Telomir-Ag2, a stabilized Silver(II) compound targeting drug-resistant infections. CEO Erez Aminov emphasized the investment's shareholder-friendly structure, noting there are no warrants or toxic financing mechanisms involved.
Telomir's primary focus is developing Telomir-1, a novel small molecule designed to lengthen telomeres—the protective end caps of chromosomes. As humans and animals age, telomere shortening increases vulnerability to degenerative diseases. The company plans to submit an Investigational New Drug (IND) application for Telomir-1 by year-end, with an initial concentration on rare disease indications to demonstrate early therapeutic efficacy.
The new investment brings Telomir's total equity funding from affiliated entities to $4 million, complemented by an undrawn $5 million non-dilutive credit line. This financial positioning provides the company with substantial resources to advance its preclinical research and potentially revolutionize approaches to aging and age-related health challenges.
Curated from InvestorBrandNetwork (IBN)
